Metformin as an adjuvant in breast cancer treatment.
| Autor: | Roshan MH; Centre for Molecular Medicine and Biobanking, Faculty of Medicine and Surgery, University of Malta, Msida, Malta., Shing YK; Pamela Youde Nethersole Eastern Hospital, Hong Kong., Pace NP; Centre for Molecular Medicine and Biobanking, Faculty of Medicine and Surgery, University of Malta, Msida, Malta. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | SAGE open medicine [SAGE Open Med] 2019 Jul 16; Vol. 7, pp. 2050312119865114. Date of Electronic Publication: 2019 Jul 16 (Print Publication: 2019). |
| DOI: | 10.1177/2050312119865114 |
| Abstrakt: | Breast cancer is one of the most common malignancies in females. It is an etiologically complex disease driven by a multitude of cellular pathways. The proliferation and spread of breast cancer is intimately linked to cellular glucose metabolism, given that glucose is an essential cellular metabolic substrate and that insulin signalling has mitogenic effects. Growing interest has focused on anti-diabetic agents in the management of breast cancer. Epidemiologic studies show that metformin reduces cancer incidence and mortality among type 2 diabetic patients. Preclinical in vitro and in vivo research provides intriguing insight into the cellular mechanisms behind the oncostatic effects of metformin. This article aims to provide an overview of the mechanisms in which metformin may elicit its anti-cancerous effects and discuss its potential role as an adjuvant in the management of breast cancer. Competing Interests: Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|